Tifacogin (recombinant tissue factor pathway inhibitor) for the treatment of patients with severe community-acquired pneumonia.

Trial Profile

Tifacogin (recombinant tissue factor pathway inhibitor) for the treatment of patients with severe community-acquired pneumonia.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Tifacogin (Primary)
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2009 Actual patient number (2136) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Actual end date (1 Jul 2008) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top